{{Drugbox
| IUPAC_name = 2-(4-ethylpiperazin-1-yl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine
| image = Blonanserin.svg
| width = 260
| image2 = Blonanserin-xtal-2012-ball-and-stick.png
| width2 = 260

<!--Clinical data-->
| tradename = Lonasen
| pregnancy_category = 
| legal_status = Rx-only
| routes_of_administration = [[Oral administration|By mouth]]

<!--Pharmacokinetic data-->
| bioavailability = 55%<ref name = PC>{{cite journal|title=Population pharmacokinetics of blonanserin in Chinese healthy volunteers and the effect of the food intake|journal=Human Psychopharmacology|date=March 2013|volume=28|issue=2|pages=134–141|doi=10.1002/hup.2290|pmid=23417765|author1=Wen, YG |author2=Shang, DW |author3=Xie, HZ |author4=Wang, XP |author5=Ni, XJ |author6=Zhang, M |author7=Lu, W |author8=Qiu, C |author9=Liu, X |author10=Li, FF |author11=Li, X |author12=Luo, FT }}</ref>
| metabolism =  [[CYP3A4]]<ref name = PC/>
| elimination_half-life = 12 h<ref name = PC/>
| excretion =  59% (urine), 30% (faeces)<ref name = PC/>

<!--Identifiers-->
| CAS_number = 132810-10-7
| ATC_prefix = none
| ATC_suffix =  
| PubChem = 125564
| ChEMBL = 178803
| ChemSpiderID = 111697
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = AQ316B4F8C
| KEGG = D01176

<!--Chemical data-->
| C=23 | H=30 | F=1 | N=3 
| molecular_weight = 367.50 g/mol
| smiles = Fc1ccc(cc1)c2cc(nc3c2CCCCCC3)N4CCN(CC)CC4
}}

'''Blonanserin''', sold under the brand name '''Lonasen''', is a relatively new [[atypical antipsychotic]] (approved by [[Pharmaceuticals and Medical Devices Agency|PMDA]] in January 2008)<ref>{{cite web|url=http://www.pmda.go.jp/english/service/pdf/list/NewdrugsFY2007.pdf |title=Archived copy |accessdate=2013-08-16 |deadurl=yes |archiveurl=https://web.archive.org/web/20130119182609/http://www.pmda.go.jp/english/service/pdf/list/NewdrugsFY2007.pdf |archivedate=2013-01-19 |df= }}</ref> commercialized by [[Dainippon Sumitomo Pharma]] in [[Japan]] and [[Korea]] for the treatment of [[schizophrenia]].<ref name = "CNS Drugs">{{cite journal|title=Blonanserin A Review of its Use in the Management of Schizophrenia|journal=CNS Drugs|date=January 2010|author1=Deeks, ED |author2=Keating, GM |volume=24|issue=1|pages=65–84|pmid=20030420|doi=10.2165/11202620-000000000-00000}}</ref> Relative to many other antipsychotics, blonanserin has an improved [[tolerability]] profile, lacking [[side effect]]s such as [[extrapyramidal symptom]]s, excessive [[sedation]], or [[hypotension]].<ref name="pmid18465651">{{cite journal | author = Heading CE | title = AD-5423 (Dainippon Pharmaceutical Co Ltd) | journal = IDrugs : the Investigational Drugs Journal | volume = 1 | issue = 7 | pages = 813–7 |date=November 1998 | pmid = 18465651 | doi = | url = }}</ref> As with many second-generation (atypical) antipsychotics it is significantly more efficacious in the treatment of the [[Schizophrenia|negative symptoms]] of schizophrenia compared to first-generation [[typical antipsychotics|(typical) antipsychotics]] such as [[haloperidol]].<ref name=kishi>{{cite journal | last1 = Kishi | first1 = T | last2 = Matsuda | first2 = Y | last3 = Nakamura | first3 = H | last4 = Iwata | first4 = N | date = Feb 2013 | title = Blonanserin for schizophrenia: Systematic review and meta-analysis of double-blind, randomized, controlled trials | url = http://www.sciencedirect.com/science/article/pii/S002239561200324X | journal = Journal of Psychiatric Research | volume = 47 | issue = 2| pages = 149–54 | doi=10.1016/j.jpsychires.2012.10.011 | pmid=23131856}}</ref>

{{TOC limit|3}}

==Medical uses==
Blonanserin is used to treat schizophrenia in Japan and South Korea but not in the US.<ref name="name">{{cite journal|last1=Wang|first1=SM|last2=Han|first2=C|last3=Lee|first3=SJ|last4=Patkar|first4=AA|last5=Masand|first5=PS|last6=Pae|first6=CU|title=Asenapine, blonanserin, iloperidone, lurasidone, and sertindole: distinctive clinical characteristics of 5 novel atypical antipsychotics.|journal=Clinical neuropharmacology|date=2013|volume=36|issue=6|pages=223–38|pmid=24201235|doi=10.1097/wnf.0b013e3182aa38c4}}</ref> 

The use of atypical antipsychotics as a first-line treatment for schizophrenia is controversial.<ref>{{cite journal|last1=McEvoy|first1=JP|title=An overview of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study.|journal=CNS spectrums|date=July 2006|volume=11|issue=7 Suppl 7|pages=4–8|pmid=16816794}}</ref>

==Adverse effects==
As with many of the atypical antipsychotics, blonanserin can elicit cardio metabolic risks. While the side effects of blonanserin – such as weight gain, cholesterol and [[triglyceride]] levels, [[glucose]] levels and other blood lipid levels – do not differ greatly from other atypical antipsychotics, the specificity of blonanserin appears to elicit milder side effects, with less weight gain in particular.<ref name=kishi/>

==Pharmacology==

===Pharmacodynamics===
Blonanserin acts as a mixed [[5-HT2A receptor|5-HT<sub>2A</sub>]] (K<sub>i</sub> = 0.812 nM) and [[D2 receptor|D<sub>2</sub> receptor]] (K<sub>i</sub> = 0.142&nbsp;nM) [[receptor antagonist|antagonist]] and also exerts some blockade of [[alpha-1 adrenergic receptor|α<sub>1</sub>-adrenergic receptor]]s (K<sub>i</sub> = 26.7&nbsp;nM).<ref name = NDT>{{cite journal|title=Profile of blonanserin for the treatment of schizophrenia|journal=Neuropsychiatric Disease and Treatment|year=2013|volume=9|pages=587–594|doi=10.2147/NDT.S34433|pmid=23766647|author1=Tenjin, T |author2=Miyamoto, S |author3=Ninomiya, Y |author4=Kitajima, R |author5=Ogino, S |author6=Miyake, N |author7=Yamaguchi, N |pmc=3677929}}</ref><ref name="pmid8093723">{{cite journal  |vauthors=Oka M, Noda Y, Ochi Y, etal | title = Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 264 | issue = 1 | pages = 158–65 |date=January 1993 | pmid = 8093723 | doi = | url = http://jpet.aspetjournals.org/cgi/pmidlookup?view=long&pmid=8093723}}</ref> Blonanserin also shows significant affinity for the [[Dopamine receptor D3|D<sub>3</sub> receptor]] (K<sub>i</sub> = 0.494 nM).<ref name=hida>{{cite journal|last1=Hida|first1=H|last2=Mouri|first2=A|last3=Mori|first3=K|last4=Matsumoto|first4=Y|last5=Seki|first5=T|last6=Taniguchi|first6=M|last7=Yamada|first7=K|last8=Iwamoto|first8=K|last9=Ozaki|first9=N|last10=Nabeshima|first10=T|last11=Noda|first11=Y|title=Blonanserin Ameliorates Phencyclidine-Induced Visual-Recognition Memory Deficits: the Complex Mechanism of Blonanserin Action Involving D<sub>3</sub>-5-HT<sub>2A</sub> and D<sub>1</sub>-NMDA Receptors in the mPFC.|journal=Neuropsychopharmacology|date=14 August 2014|pmid=25120077|doi=10.1038/npp.2014.207|volume=40|pages=601–13|pmc=4289947}}</ref> It lacks significant [[affinity (pharmacology)|affinity]] for numerous other sites including the [[5-HT1A receptor|5-HT<sub>1A</sub>]], [[5-HT3 receptor|5-HT<sub>3</sub>]], [[D1 receptor|D<sub>1</sub>]], [[alpha-2 adrenergic receptor|α<sub>2</sub>-adrenergic]], [[beta-adrenergic receptor|β-adrenergic]], [[H1 receptor|H<sub>1</sub>]], and [[muscarinic acetylcholine receptor|mACh receptor]]s and the [[monoamine transporter]]s,<ref name="pmid8093723"/> though it does possess low affinity for the [[sigma receptor]] (IC<sub>50</sub> = 286 nM).<ref name="pmid8093723"/>

Blonanserin has a relatively high affinity towards the [[5-HT6 receptor|5-HT<sub>6</sub> receptor]] perhaps underpinning its recently unveiled efficacy in treating the cognitive symptoms of schizophrenia.<ref name = NDT/><ref>{{cite journal|title=Effect of blonanserin on cognitive function in antipsychotic-naïve first-episode schizophrenia|journal=Human Psychopharmacology|date=January 2012|volume=27|issue=1|pages=90–100|doi=10.1002/hup.1276|pmid=22278973|author1=Tenjin, T |author2=Miyamoto, S |author3=Miyake, N |author4=Ogino, S |author5=Kitajima, R |author6=Ojima, K |author7=Arai, J |author8=Teramoto, H |author9=Tsukahara, S |author10=Ito, Y |author11=Tadokoro, M |author12=Anai, K |author13=Funamoto, Y |author14=Kaneda, Y |author15=Sumiyoshi, T |author16=Yamaguchi, N }}</ref> The  efficacy of blonanserin can in part be attributed to its chemical structure, which is unique from those of other atypical antipsychotics.<ref name=suzuki>{{cite journal|last1=Suzuki|first1=K|last2=Hiyama|first2=Y|last3=Une|first3=T|last4=Fujiwara|first4=I|title=Crystal structure of an antipsychotic agent, 2-(4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine (blonanserin).|journal=Analytical Sciences|date=November 2002|volume=18|issue=11|pages=1289–90|pmid=12458724|doi=10.2116/analsci.18.1289}}</ref> Specifically, the addition of hydroxyl groups to blonanserin's unique eight membered ring results in the (R) stereoisomer of the compound demonstrating increased affinity for the indicated targets.<ref>{{cite journal|last1=Ochi|first1=T|last2=Sakamoto|first2=M|last3=Minamida|first3=A|last4=Suzuki|first4=K|last5=Ueda|first5=T|last6=Une|first6=T|last7=Toda|first7=H|last8=Matsumoto|first8=K|last9=Terauchi|first9=Y|title=Syntheses and properties of the major hydroxy metabolites in humans of blonanserin AD-5423, a novel antipsychotic agent.|journal=Bioorganic & Medicinal Chemistry Letters|date=15 February 2005|volume=15|issue=4|pages=1055–9|pmid=15686911|doi=10.1016/j.bmcl.2004.12.028}}</ref>

{| class="wikitable sortable"
|-
! Receptor !! K<sub>i</sub> [nM] (Blonanserin)* <ref name = NDT/>!! K<sub>i</sub> [nM] (N-deethylblonanserin)* <ref name = "CNS Drugs"/>
|-
| [[Dopamine D1 receptor|D<sub>1</sub>]] || 1070 || 1020
|-
| [[Dopamine D2 receptor|D<sub>2</sub>]] || 0.142 || 1.38
|-
| [[Dopamine D3 receptor|D<sub>3</sub>]] || 0.494 || 0.23
|-
| [[Dopamine D4 receptor|D<sub>4</sub>]] || 150 || -
|-
| [[Dopamine D5 receptor|D<sub>5</sub>]] || 2600 || -
|-
| [[5-HT1A receptor|5-HT<sub>1A</sub>]] || 804 || -
|-
| [[5-HT2A receptor|5-HT<sub>2A</sub>]] || 0.812 || 1.28
|-
| [[5-HT2C receptor|5-HT<sub>2C</sub>]] || 26.4 || 4.50
|-
| [[5-HT6 receptor|5-HT<sub>6</sub>]] || 11.7 || 5.03
|-
| [[5-HT7 receptor|5-HT<sub>7</sub>]] || 183 || -
|-
| [[Alpha-1 adrenergic receptor|α<sub>1</sub>]] || 26.7 (Rat brain) || 206 (Rat receptor)
|-
| [[Alpha-2 adrenergic receptor|α<sub>2</sub>]] || 530 (Rat cloned) || -
|-
| [[Muscarinic acetylcholine receptor M1|M<sub>1</sub>]] || 100 || -
|-
| [[Histamine H1 receptor|H<sub>1</sub>]] || 765 || -
|}
<nowiki>*</nowiki> Towards human receptors unless otherwise specified.

====Action at the Dopamine-D<sub>3</sub> receptor====
Blonanserin has antagonistic action at dopamine-D<sub>3</sub> receptors that potentiates [[phosphorylation]] levels of [[Protein kinase A]] (PKA) and counteracts decreased activity at the dopamine-D<sub>1</sub> and/or [[NMDA]] receptors, thus potentiating [[GABA]] induced Cl- currents.<ref name=hida/><ref name=yokota>{{cite journal|last1=Yokota|first1=K|last2=Tatebayashi|first2=H|last3=Matsuo|first3=T|last4=Shoge|first4=T|last5=Motomura|first5=H|last6=Matsuno|first6=T|last7=Fukuda|first7=A|last8=Tashiro|first8=N|title=The effects of neuroleptics on the GABA-induced Cl- current in rat dorsal root ganglion neurons: differences between some neuroleptics.|journal=British Journal of Pharmacology|date=March 2002|volume=135|issue=6|pages=1547–55|pmid=11906969|doi=10.1038/sj.bjp.0704608|pmc=1573270}}</ref> [[Olanzapine]] does not appear to affect PKA activity.<ref name=hida/><ref>{{cite journal|last1=Nagai|first1=T|last2=Noda|first2=Y|last3=Une|first3=T|last4=Furukawa|first4=K|last5=Furukawa|first5=H|last6=Kan|first6=QM|last7=Nabeshima|first7=T|title=Effect of AD-5423 on animal models of schizophrenia: phencyclidine-induced behavioral changes in mice.|journal=NeuroReport|date=10 February 2003|volume=14|issue=2|pages=269–72|pmid=12598744|doi=10.1097/00001756-200302100-00023}}</ref> Many antipsychotics, such as haloperidol, [[chlorpromazine]], [[risperidone]] and olanzapine primarily antagonize serotonin 5-HT2A and dopamine-D<sub>2</sub> receptors and lack known action at dopamine-D<sub>2/3</sub> receptors.<ref name=hida/><ref name=suzuki/>

{| class="wikitable"
|-
| [[File:Blonanserin Cartoon.jpg|Blonanserin Cartoon]]
|-
| '''Blonanserin action at dopamine-D<sub>3</sub> receptor.''' Cartoon of blonanserin's antagonistic impact at the dopamine-D<sub>3</sub> receptor, reversing inhibition of PKA activity (also regulated by dopamine-D<sub>1</sub> and NMDA activity) thus potentiating GABA induced Cl- current. Inset illustrates uninterrupted [[dopamine]] (DA) activity at the dopamine-D<sub>3</sub> receptor. Inspired by Hida et al. (2014) and Yokota et al. (2002).<ref name=hida/><ref name=yokota/>
|}

===Pharmacokinetics===
Blonanserin is administered 4&nbsp;mg orally 2 times a day or 8&nbsp;mg once a day, for an adult male with a body mass index between 19–24&nbsp;kg/m<sup>2</sup> and a body weight equal to or greater than 50&nbsp;kg.<ref name = chen>{{cite journal|last1=Chen|first1=X|last2=Wang|first2=H|last3=Jiang|first3=J|last4=Chen|first4=R|last5=Zhou|first5=Y|last6=Zhong|first6=W|last7=Liu|first7=H|last8=Hu|first8=P|title=The pharmacokinetic and safety profiles of blonanserin in healthy Chinese volunteers after single fasting doses and single and multiple postprandial doses.|journal=Clinical drug investigation|date=March 2014|volume=34|issue=3|pages=213–22|pmid=24399453|doi=10.1007/s40261-013-0167-9}}</ref> The drug is absorbed by a two compartment (central and peripheral) model with first-order absorption and elimination.<ref name=wen>{{cite journal|last1=Wen|first1=YG|last2=Shang|first2=DW|last3=Xie|first3=HZ|last4=Wang|first4=XP|last5=Ni|first5=XJ|last6=Zhang|first6=M|last7=Lu|first7=W|last8=Qiu|first8=C|last9=Liu|first9=X|last10=Li|first10=FF|last11=Li|first11=X|last12=Luo|first12=FT|title=Population pharmacokinetics of blonanserin in Chinese healthy volunteers and the effect of the food intake.|journal=Human psychopharmacology|date=March 2013|volume=28|issue=2|pages=134–41|pmid=23417765|doi=10.1002/hup.2290}}</ref> The [[half-life]] of blonanserin is dependent on the dose. A single dose of 4&nbsp;mg has a half-life of 7.7 ± 4.63 h and a single dose of 8&nbsp;mg has a half-life of 11.9 ± 4.3 h.<ref name=chen/> The increase of half-life with dose is possibly attributed to there being more individual concentration per time points below the lower limit necessary for quantification in the lower single dose.<ref name=chen/>

Blonanserin is not a charged compound and exhibits very little [[chemical polarity]].  The [[polar surface area]] of Blonanserin is 19.7 Å<ref name=chem>{{cite web|url=http://www.chemicalize.org/structure/#!mol=Blonanserin|title=Properties Viewer}}.</ref> It is commonly accepted that a compound needs to have polar surface area less than 90 Å to cross the [[blood brain barrier]] so blonanserin is expected to be quite permeable as is demonstrated by a high brain/ plasma ratio of 3.88.<ref>{{cite journal|last1=Tateno|first1=A|last2=Arakawa|first2=R|last3=Okumura|first3=M|last4=Fukuta|first4=H|last5=Honjo|first5=K|last6=Ishihara|first6=K|last7=Nakamura|first7=H|last8=Kumita|first8=S|last9=Okubo|first9=Y|title=Striatal and extrastriatal dopamine D2 receptor occupancy by a novel antipsychotic, blonanserin: a PET study with [11C]raclopride and [11C]FLB 457 in schizophrenia.|journal=Journal of Clinical Psychopharmacology|date=Apr 2013|volume=33|issue=2|pages=162–9|pmid=23422369|doi=10.1097/jcp.0b013e3182825bce}}</ref>

Due to the good permeability of blonanserin, the [[volume of distribution]] in the [[central nervous system]] is greater than that in the periphery (Vd central = 9500 L, Vd periphery = 8650 L) although it is slower to absorb into the central compartment.<ref name=wen/>

Blonanserin does not meet the criteria in [[Lipinski's rule of five]].<ref name=chem/> 

====Effects of food intake====
Food intake slows the absorption of blonanserin and increases the bioavailability peripherally relative to centrally.<ref name=wen/> Single fasting doses are safe and the effects of feeding intake are possibly explained by an interaction between blonanserin and [[CYP3A4|Cytochrome P450 3A4]] in the gut.<ref name=chen/>

==See also==
* [[Dopamine receptor D3|Dopamine Receptor D<sub>3</sub>]]
* [[Lipinski's rule of five]]

==References==
{{Reflist|2}}


{{Antipsychotics}}
{{Dopamine receptor modulators}}
{{Serotonin receptor modulators}}

[[Category:5-HT2 antagonists]]
[[Category:Atypical antipsychotics]]
[[Category:D2 antagonists]]
[[Category:D3 antagonists]]
[[Category:Fluoroarenes]]
[[Category:Piperazines]]